Page 5 - Axsm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Axsm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Axsm Today - Breaking & Trending Today

Axsome Therapeutics (NASDAQ:AXSM) Now Covered by Analysts at Royal Bank of Canada

Royal Bank of Canada started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Thursday, Marketbeat Ratings reports. The firm issued an outperform rating and a $126.00 price target on the stock. AXSM has been the topic of a number of other reports. Cantor Fitzgerald reiterated an overweight rating […] ....

Nova Scotia , United States , Piper Sandler , Royal Bank , Vanguard Group Inc , Axsome Therapeutics Inc , Cantor Fitzgerald , Blackrock Inc , Axsome Therapeutics , Free Report , Marketbeat Ratings , Moderate Buy , Get Free Report , State Street Corp , Street Corp , Axsome Therapeutics Daily , Nasdaq Axsm , Initiated Coverage , Royal Bank Of Canada ,

Axsome Therapeutics' (AXSM) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report released on Tuesday, Marketbeat Ratings reports. HC Wainwright currently has a $180.00 price target on the stock. A number of other equities research analysts have also recently commented on AXSM. Cantor Fitzgerald restated an overweight rating […] ....

United States , Cantor Fitzgerald , Axsome Therapeutics Inc , Blackrock Inc , Vanguard Group Inc , Axsome Therapeutics , Free Report , Marketbeat Ratings , Moderate Buy , Get Free Report , Axsome Therapeutics Daily , Nasdaq Axsm , Reiterated Rating , Hc Wainwright ,

Axsome Therapeutics (NASDAQ:AXSM) Receives "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $108.00 price objective on the stock. Several other research analysts have also weighed in on AXSM. HC Wainwright restated a buy rating and set a $180.00 target […] ....

United States , Bellevue Group , Perceptive Advisors , Axsome Therapeutics Inc , Cantor Fitzgerald , Axsome Therapeutics , Free Report , Moderate Buy , Get Free Report , Point Capital Management , Global Partners , Rhumbline Advisers , Axsome Therapeutics Daily , Nasdaq Axsm , Reiterated Rating ,

Axsome Therapeutics (NASDAQ:AXSM) Coverage Initiated at Citigroup

Citigroup started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $125.00 target price on the stock. AXSM has been the topic of several other reports. HC Wainwright restated a buy rating and set a $180.00 […] ....

New Zealand General , New Zealand , United States , Wellington Management Group , Axsome Therapeutics Inc , Deutsche Bank , Cantor Fitzgerald , Manufacturers Life Insurance Company , Axsome Therapeutics , Free Report , Marketbeat Ratings , Moderate Buy , Therapeutics Stock Down , Get Free Report , Management Group , Ivy Capital Management , Axsome Therapeutics Daily , Nasdaq Axsm , Initiated Coverage , Citigroup Inc ,

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have received a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 […] ....

United States , William Blair , Mark Coleman , Axsome Therapeutics Inc , Fifth Third Bancorp , Tower Research Capital , Harbour Investments Inc , Axsome Therapeutics Company Profile , Third Bancorp , Axsome Therapeutics , Get Free Report , Director Mark Coleman , Financial Advisors , Research Capital , Dark Forest Capital Management , Get Free , Axsome Therapeutics Daily , Nasdaq Axsm ,